Bogacz-Piaseczyńska Agnieszka, Bożek Andrzej, Pastuszczak Maciej, Zalejska-Fiolka Jolanta
Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland.
Department of Biochemistry, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland.
Postepy Dermatol Alergol. 2023 Aug;40(4):542-547. doi: 10.5114/ada.2023.129456. Epub 2023 Jul 14.
Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD).
To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens.
In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months' AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed.
Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites ( < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT.
HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.
变应原免疫疗法(AIT)对特应性皮炎(AD)尚无明确推荐。
评估AIT对尘螨过敏且具有不同抗原基线分子谱的AD患者中尘螨(HDM)的影响。
在这项安慰剂对照研究中,纳入了61例有中重度AD过敏症状且对HDM过敏的患者。他们接受了为期12个月的使用HDM变应原提取物或安慰剂的AIT。作者将AIT 1年后AD改善标准设定为体表面积百分比(%BSA)、总评分(TMS)和湿疹面积及严重程度指数(EASI)评分较基线至少降低50%。此外,分析了单个HDM分子对最终AIT效果的影响。
最终,在24例脱敏患者中,15例在HDM AIT治疗12个月后达到了预期的阳性效果。在随访1年后,接受安慰剂治疗的患者中没有一例AD改善至少50%。多敏患者比仅对螨虫过敏的患者更难达到预期的HDM AIT效果(<0.05)。对重组粉尘螨1(rDer p 1)(比值比=4.35,95%置信区间:4.01 - 4.56)和/或重组粉尘螨2(rDer p 2)(OR = 2.16,95%置信区间:1.98 - 2.33)和/或重组屋尘螨2(rDer f 2)(OR = 1.41,95%置信区间:1.55 - 1.78)分子致敏显著提高了AIT的疗效。HDM AIT作为一种附加疗法,可能对中重度AD且对HDM过敏的患者有帮助。各种HDM分子可能会影响预期的AIT效果。对rDer p 1(OR = 4.35,95%置信区间:4.01 - 4.56)和/或rDer p 2(OR = 2.16,95%置信区间:1.98 - 2.33)和/或rDer f 2(OR = 1.41,95%置信区间:1.55 - 1.78)分子致敏显著提高了AIT的疗效。
HDM AIT作为一种附加疗法,可能对中重度AD且对HDM过敏的患者有帮助。各种HDM分子可能会影响预期的AIT效果。